EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Adjuvant treatment for locally advanced gastric cancer: an Asian perspective

Hyung-Don Kim, Min-Hee Ryu, Yoon-Koo Kang iD

Gastric Cancer · 2024-05 · 27 (3) · 439-450

DOI: 10.1007/s10120-024-01484-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Gastric Cancer, online erschienen am 15.03.2024. Verfasst von Hyung-Don Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88,Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Kore…. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standard adjuvant treatment for locally advanced gastric cancer (LAGC) is regionally different. Whereas perioperative chemotherapy is the standard in Western populations, D2 gastrectomy followed by adjuvant chemotherapy has been the standard in East Asia. Recently, the pivotal phase 3 PRODIGY and RESOLVE studies have demonstrated survival benefits of adding neoadjuvant chemotherapy to surgery followed by adjuvant chemotherapy over up-front surgery followed by adjuvant chemotherapy in Asian patients. Based on these results, neoadjuvant chemotherapy is considered one of the viable options for patients with LAGC. In this review, various aspects of neoadjuvant chemotherapy will be discussed for its optimal application in Asia. Candidates for neoadjuvant chemotherapy should be carefully chosen in consideration of the inaccurate aspects of radiological clinical staging and its potential benefit over up-front surgery followed by a decision on adjuvant chemotherapy according to the pathological stage. Efforts should continuously be made to optimally apply neoadjuvant chemotherapy to patients with LAGC, considering various factors, including a more accurate radiological assessment of the tumor burden and the optimization of post-operative chemotherapy. Future neoadjuvant trials involving novel agents for Asian patients should be designed based on proven Asian regimens rather than adopting Western regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansNeoplasm StagingGastrectomyChemotherapy, AdjuvantNeoadjuvant TherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Adjuvant chemotherapyAsiaGastric cancerNeoadjuvant chemotherapy

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88,Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88,Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. ykkang@amc.seoul.kr.

ORCID-Profile: Yoon-Koo Kang

Zitieren

APA

Kim, H. D., Ryu, M. H., & Kang, Y. K. (2024). Adjuvant treatment for locally advanced gastric cancer: an Asian perspective. Gastric Cancer, 27(3), 439-450. https://doi.org/10.1007/s10120-024-01484-8

Vancouver

Kim HD, Ryu MH, Kang YK. Adjuvant treatment for locally advanced gastric cancer: an Asian perspective. Gastric Cancer. 2024;27(3):439-450. doi:10.1007/s10120-024-01484-8

BibTeX
@article{Kim2024,
  author = {Kim, Hyung-Don and Ryu, Min-Hee and Kang, Yoon-Koo},
  title = {Adjuvant treatment for locally advanced gastric cancer: an Asian perspective},
  journal = {Gastric Cancer},
  year = {2024},
  volume = {27},
  number = {3},
  pages = {439--450},
  doi = {10.1007/s10120-024-01484-8}
}
Kostenlos starten →